{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:15:25Z","timestamp":1792984525930,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CEA"},{"name":"INSERM"},{"name":"UGA"},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"amro"},{"name":"ARC"},{"name":"FRM"},{"name":"FMR"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0885-1","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T16:17:33Z","timestamp":1535645853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer"],"prefix":"10.1186","volume":"37","author":[{"given":"Marie","family":"Ouarn\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Boneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Desroches-Castan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Soleilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Peyruchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"issue":"5","key":"885_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"6","key":"885_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/med.21452","volume":"37","author":"R Ronca","year":"2017","unstructured":"Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: regulators and clinical implications. Med Res Rev. 2017;37(6):1231\u201374.","journal-title":"Med Res Rev"},{"issue":"2","key":"885_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328\u201335.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"885_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605\u201322.","journal-title":"Cancer Cell"},{"issue":"4","key":"885_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409\u201326.","journal-title":"Angiogenesis"},{"issue":"26","key":"885_CR6","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","volume":"117","author":"SI Cunha","year":"2011","unstructured":"Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011;117(26):6999\u20137006.","journal-title":"Blood"},{"issue":"11","key":"885_CR7","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-13-2788","volume":"20","author":"RS Bhatt","year":"2014","unstructured":"Bhatt RS, Atkins MB. Molecular pathways: can Activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res. 2014;20(11):2838\u201345.","journal-title":"Clin Cancer Res"},{"key":"885_CR8","doi-asserted-by":"crossref","unstructured":"Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S et al: Activin receptor-like kinase 1 modulates transforming growth factor- beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000, 97(6):2626\u20132631.","DOI":"10.1073\/pnas.97.6.2626"},{"issue":"3","key":"885_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/81634","volume":"26","author":"LD Urness","year":"2000","unstructured":"Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1 [in process citation]. Nat Genet. 2000;26(3):328\u201331.","journal-title":"Nat Genet"},{"issue":"2","key":"885_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ng0696-189","volume":"13","author":"DW Johnson","year":"1996","unstructured":"Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13(2):189\u201395.","journal-title":"Nat Genet"},{"issue":"4","key":"885_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng1294-345","volume":"8","author":"KA McAllister","year":"1994","unstructured":"McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345\u201351.","journal-title":"Nat Genet"},{"issue":"26","key":"885_CR12","doi-asserted-by":"publisher","first-page":"25111","DOI":"10.1074\/jbc.M503328200","volume":"280","author":"MA Brown","year":"2005","unstructured":"Brown MA, Zhao Q, Baker KA, Naik C, Chen C, Pukac L, Singh M, Tsareva T, Parice Y, Mahoney A, et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem. 2005;280(26):25111\u20138.","journal-title":"J Biol Chem"},{"issue":"5","key":"885_CR13","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","volume":"109","author":"L David","year":"2007","unstructured":"David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109(5):1953\u201361.","journal-title":"Blood"},{"issue":"24","key":"885_CR14","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1074\/jbc.275.24.17937","volume":"275","author":"AF Miller","year":"2000","unstructured":"Miller AF, Harvey SA, Thies RS, Olson MS. Bone morphogenetic protein-9. An autocrine\/paracrine cytokine in the liver. J Biol Chem. 2000;275(24):17937\u201345.","journal-title":"J Biol Chem"},{"issue":"2","key":"885_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0925-4773(98)00221-4","volume":"80","author":"H Neuhaus","year":"1999","unstructured":"Neuhaus H, Rosen V, Thies RS. Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily. Mech Dev. 1999;80(2):181\u20134.","journal-title":"Mech Dev"},{"issue":"2","key":"885_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00018-011-0751-1","volume":"69","author":"M Bidart","year":"2012","unstructured":"Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, Feige JJ, Bailly S. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cellular and molecular life sciences : CMLS. 2012;69(2):313\u201324.","journal-title":"Cellular and molecular life sciences : CMLS"},{"issue":"29","key":"885_CR17","doi-asserted-by":"publisher","first-page":"11887","DOI":"10.1073\/pnas.1306074110","volume":"110","author":"H Chen","year":"2013","unstructured":"Chen H, Brady Ridgway J, Sai T, Lai J, Warming S, Chen H, Roose-Girma M, Zhang G, Shou W, Yan M. Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development. Proc Natl Acad Sci U S A. 2013;110(29):11887\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"885_CR18","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1038\/bcj.2014.16","volume":"4","author":"OE Olsen","year":"2014","unstructured":"Olsen OE, Wader KF, Misund K, Vatsveen TK, Ro TB, Mylin AK, Turesson I, Stordal BF, Moen SH, Standal T, et al. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood cancer journal. 2014;4:e196.","journal-title":"Blood cancer journal"},{"issue":"33","key":"885_CR19","doi-asserted-by":"publisher","first-page":"27313","DOI":"10.1074\/jbc.M112.377960","volume":"287","author":"SA Townson","year":"2012","unstructured":"Townson SA, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J, Ucran JA, Liharska K, Underwood KW, Seehra J, et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem. 2012;287(33):27313\u201325.","journal-title":"J Biol Chem"},{"issue":"25","key":"885_CR20","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1182\/blood-2012-01-407593","volume":"119","author":"N Ricard","year":"2012","unstructured":"Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, Lee SJ, Bidart M, Feige JJ, Bailly S. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood. 2012;119(25):6162\u201371.","journal-title":"Blood"},{"issue":"9","key":"885_CR21","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1242\/dev.01094","volume":"131","author":"H Chen","year":"2004","unstructured":"Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, et al. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development. 2004;131(9):2219\u201331.","journal-title":"Development"},{"issue":"4","key":"885_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2012-12-472142","volume":"122","author":"S Levet","year":"2013","unstructured":"Levet S, Ciais D, Merdzhanova G, Mallet C, Zimmers TA, Lee SJ, Navarro FP, Texier I, Feige JJ, Bailly S, et al. Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation. Blood. 2013;122(4):598\u2013607.","journal-title":"Blood"},{"issue":"25","key":"885_CR23","doi-asserted-by":"publisher","first-page":"E3207","DOI":"10.1073\/pnas.1508386112","volume":"112","author":"S Levet","year":"2015","unstructured":"Levet S, Ouarne M, Ciais D, Coutton C, Subileau M, Mallet C, Ricard N, Bidart M, Debillon T, Faravelli F, et al. BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus. Proc Natl Acad Sci U S A. 2015;112(25):E3207\u201315.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"885_CR24","doi-asserted-by":"crossref","unstructured":"Goumans MJ, Zwijsen A, Ten Dijke P, Bailly S. Bone morphogenetic proteins in vascular homeostasis and disease. Cold Spring Harb Perspect Biol. 2018;10(2)","DOI":"10.1101\/cshperspect.a031989"},{"issue":"4","key":"885_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1042\/BST20160093","volume":"44","author":"AG de Vinuesa","year":"2016","unstructured":"de Vinuesa AG, Bocci M, Pietras K, Ten Dijke P. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochem Soc Trans. 2016;44(4):1142\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"885_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1158\/1535-7163.MCT-09-0650","volume":"9","author":"D Mitchell","year":"2010","unstructured":"Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, et al. ALK1-fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther. 2010;9(2):379\u201388.","journal-title":"Mol Cancer Ther"},{"key":"885_CR27","doi-asserted-by":"crossref","unstructured":"van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P: Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. The J Biol Chem 2012, 287(22):18551\u201318561.","DOI":"10.1074\/jbc.M111.338103"},{"key":"885_CR28","doi-asserted-by":"crossref","unstructured":"Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P, Pietras K: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010, 207(1):85\u2013100, S101-105.","DOI":"10.1084\/jem.20091309"},{"issue":"4","key":"885_CR29","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","volume":"71","author":"DD Hu-Lowe","year":"2011","unstructured":"Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, et al. Targeting Activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 2011;71(4):1362\u201373.","journal-title":"Cancer Res"},{"issue":"12","key":"885_CR30","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-14-3706","volume":"75","author":"SI Cunha","year":"2015","unstructured":"Cunha SI, Bocci M, Lovrot J, Eleftheriou N, Roswall P, Cordero E, Lindstrom L, Bartoschek M, Haller BK, Pearsall RS, et al. Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast Cancer. Cancer Res. 2015;75(12):2445\u201356.","journal-title":"Cancer Res"},{"issue":"23","key":"885_CR31","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1002\/cncr.30317","volume":"122","author":"A Jimeno","year":"2016","unstructured":"Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, et al. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016;122(23):3641\u20139.","journal-title":"Cancer"},{"issue":"11","key":"885_CR32","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.jtho.2016.06.024","volume":"11","author":"P Wheatley-Price","year":"2016","unstructured":"Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, et al. A phase II study of PF-03446962 in patients with advanced malignant pleural mesothelioma. CCTG trial IND.207. J Thorac Oncol. 2016;11(11):2018\u201321.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"885_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069535","volume":"8","author":"B Herrera","year":"2013","unstructured":"Herrera B, Garcia-Alvaro M, Cruz S, Walsh P, Fernandez M, Roncero C, Fabregat I, Sanchez A, Inman GJ. BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS One. 2013;8(7):e69535.","journal-title":"PLoS One"},{"issue":"5","key":"885_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13402-014-0197-1","volume":"37","author":"S Wan","year":"2014","unstructured":"Wan S, Liu Y, Weng Y, Wang W, Ren W, Fei C, Chen Y, Zhang Z, Wang T, Wang J, et al. BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells. Cell Oncol (Dordr). 2014;37(5):363\u201375.","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"885_CR35","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00432-011-1047-4","volume":"137","author":"K Wang","year":"2011","unstructured":"Wang K, Feng H, Ren W, Sun X, Luo J, Tang M, Zhou L, Weng Y, He TC, Zhang Y. BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin Oncol. 2011;137(11):1687\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"885_CR36","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11033-013-2982-8","volume":"41","author":"W Ren","year":"2014","unstructured":"Ren W, Sun X, Wang K, Feng H, Liu Y, Fei C, Wan S, Wang W, Luo J, Shi Q, et al. BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol Biol Rep. 2014;41(3):1373\u201383.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"885_CR37","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/j.1349-7006.2010.01648.x","volume":"101","author":"L Ye","year":"2010","unstructured":"Ye L, Bokobza S, Li J, Moazzam M, Chen J, Mansel RE, Jiang WG. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci. 2010;101(10):2137\u201344.","journal-title":"Cancer Sci"},{"issue":"6B","key":"885_CR38","first-page":"3905","volume":"25","author":"A Ewens","year":"2005","unstructured":"Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res. 2005;25(6B):3905\u201315.","journal-title":"Anticancer Res"},{"issue":"19","key":"885_CR39","doi-asserted-by":"crossref","first-page":"30621","DOI":"10.18632\/oncotarget.15695","volume":"8","author":"Y Yang","year":"2017","unstructured":"Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, Anver MR, Haines DC, Martin P, Green JE, et al. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 2017;8(19):30621\u201343.","journal-title":"Oncotarget"},{"issue":"5","key":"885_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/dvg.20212","volume":"44","author":"I Imayoshi","year":"2006","unstructured":"Imayoshi I, Ohtsuka T, Metzger D, Chambon P, Kageyama R. Temporal regulation of Cre recombinase activity in neural stem cells. Genesis. 2006;44(5):233\u20138.","journal-title":"Genesis"},{"key":"885_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12329","volume":"7","author":"C Depner","year":"2016","unstructured":"Depner C, Zum Buttel H, Bogurcu N, Cuesta AM, Aburto MR, Seidel S, Finkelmeier F, Foss F, Hofmann J, Kaulich K, et al. EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. Nat Commun. 2016;7:12329.","journal-title":"Nat Commun"},{"issue":"11","key":"885_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.neo.2015.11.003","volume":"17","author":"A Varadaraj","year":"2015","unstructured":"Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K. Epigenetic regulation of GDF2 suppresses Anoikis in ovarian and breast epithelia. Neoplasia. 2015;17(11):826\u201338.","journal-title":"Neoplasia"},{"issue":"5","key":"885_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096816","volume":"9","author":"W Ren","year":"2014","unstructured":"Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, Zhang Z, Wang T, Wang J, Zhou L, et al. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1\/2 and PI3K\/AKT pathways. PLoS One. 2014;9(5):e96816.","journal-title":"PLoS One"},{"issue":"8","key":"885_CR44","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/CIRCRESAHA.107.165530","volume":"102","author":"L David","year":"2008","unstructured":"David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ, Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008;102(8):914\u201322.","journal-title":"Circ Res"},{"issue":"3","key":"885_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1549-8719.2010.00029.x","volume":"17","author":"D Fukumura","year":"2010","unstructured":"Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010;17(3):206\u201325.","journal-title":"Microcirculation"},{"issue":"6","key":"885_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","volume":"30","author":"JS Park","year":"2016","unstructured":"Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2016;30(6):953\u201367.","journal-title":"Cancer Cell"},{"issue":"1","key":"885_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.11.024","volume":"21","author":"VG Cooke","year":"2012","unstructured":"Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21(1):66\u201381.","journal-title":"Cancer Cell"},{"issue":"10","key":"885_CR48","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.molonc.2016.10.002","volume":"10","author":"V Brand","year":"2016","unstructured":"Brand V, Lehmanna C, Umkehrera C, Bissingera S, Thierb M, de Woutersb M, Raemscha R, Jucknischkea U, Haasc A, Breuerc S, et al. Impact of selective anti-BMP9 treatment on tumor cells and tumor angiogenesis. Mol Oncol. 2016;10(10):1603\u201320.","journal-title":"Mol Oncol"},{"issue":"51","key":"885_CR49","doi-asserted-by":"publisher","first-page":"84314","DOI":"10.18632\/oncotarget.12604","volume":"7","author":"NM Eleftheriou","year":"2016","unstructured":"Eleftheriou NM, Sjolund J, Bocci M, Cortez E, Lee SJ, Cunha SI, Pietras K. Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-beta signaling. Oncotarget. 2016;7(51):84314\u201325.","journal-title":"Oncotarget"},{"issue":"6249","key":"885_CR50","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aad0862","volume":"349","author":"LB Rivera","year":"2015","unstructured":"Rivera LB, Bergers G. CANCER. Tumor angiogenesis, from foe to friend. Science. 2015;349(6249):694\u20135.","journal-title":"Science"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0885-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T14:40:23Z","timestamp":1604846423000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0885-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0885-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"7 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the institutional guidelines and those formulated by the European Community for the Use of Experimental Animals. The ethical approval for these experiments was given by the French ministry under the number APAFIS#7345\u20132016102512011432 v2.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"209"}}